By incorporating a transferrin receptor (TfR)-binding peptide, T7, onto the exosome surface, researchers have enhanced targeting of TfR-rich GBM cells, such as C6 cells, compared to unmodified or RVG-modified exosomes [54]. Here, TFRC is linked to glioblastoma.